{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Avidity Biosciences, Inc.
Is Avidity Biosciences, Inc. technically bullish or bearish?
As of September 26, 2025, Avidity Biosciences, Inc. shows a bullish technical trend with strong momentum from MACD and moving averages, despite a recent underperformance over the past month compared to the S&P 500.
Is Avidity Biosciences, Inc. technically bullish or bearish?
As of September 26, 2025, Avidity Biosciences is in a bullish trend with strong indicators, having outperformed the S&P 500 year-to-date with a 47.70% return, but underperformed in the last month with a -8.71% return.
Avidity Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics
Avidity Biosciences, Inc. has recently revised its evaluation amid market dynamics, with its stock price rising to $42.34. The company has experienced significant volatility over the past year, with a 52-week high of $56.00 and a low of $21.51, while showing mixed technical indicators.
Is Avidity Biosciences, Inc. technically bullish or bearish?
As of September 19, 2025, Avidity Biosciences, Inc. has a mildly bullish technical trend, supported by positive weekly and monthly MACD indicators, bullish moving averages, and outperformance against the S&P 500 over the past week, despite mixed signals in longer-term metrics.
Is Avidity Biosciences, Inc. technically bullish or bearish?
As of September 19, 2025, Avidity Biosciences, Inc. shows a mildly bullish technical trend, supported by positive MACD indicators and Bollinger Bands, but has underperformed the S&P 500 recently despite a strong year-to-date return of 41.20%.
Is Avidity Biosciences, Inc. technically bullish or bearish?
As of August 28, 2025, Avidity Biosciences, Inc. shows a bullish technical trend supported by MACD and moving averages, outperforming the S&P 500 year-to-date with a 43.78% return, despite a -6.32% return over the past year.
Avidity Biosciences Stock Hits Day Low of $39.83 Amid Price Pressure
Avidity Biosciences, Inc. saw a significant decline in its stock value today, reaching an intraday low. Despite recent strong performance metrics, including notable gains over the past month and year, the company continues to face financial challenges, reporting negative results and concerning operating cash flow.
Is Avidity Biosciences, Inc. technically bullish or bearish?
As of June 17, 2025, Avidity Biosciences, Inc. is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD and KST, with a recent -4.68% return contrasting the positive performance of the S&P 500.
Who are in the management team of Avidity Biosciences, Inc.?
As of March 2022, Avidity Biosciences, Inc.'s management team includes Dr. Troy Wilson (Executive Chairman), Ms. Sarah Boyce (President and CEO), and several directors, including Ms. Jean Kim, Ms. Tamar Thompson, and independent directors Dr. Noreen Henig, Dr. Edward Kaye, and Mr. Carsten Boess. The team features a blend of executive leadership and independent oversight.
What does Avidity Biosciences, Inc. do?
Avidity Biosciences, Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOC) for serious diseases, with a market cap of approximately $3.54 billion. As of March 2025, it reported net sales of $2 million and a net loss of $116 million.
How big is Avidity Biosciences, Inc.?
As of Jun 18, Avidity Biosciences, Inc. has a market capitalization of $3.54 billion, with recent net sales of $8.92 million and a net profit of -$369.22 million. The company reported shareholder's funds of $1.42 billion and total assets of $1.56 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
